Activity
Mon
Wed
Fri
Sun
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
What is this?
Less
More

Owned by Lily

All-in-One Peptide Research Community.🧪 Peptide education, research, GLP-1s, compounds, storage & vendor insights.🧬 Learn. Research. Stay Ahead.🔬

Skoolers
148.3k
Free
95 contributions to Neuro Peptide
Selank Peptide: Benefits, Mechanism of Action, Anxiety Research and Safety
An Overview Could a small synthetic peptide influence anxiety without producing the sedation commonly associated with some traditional anti-anxiety medications? That is one of the questions researchers have investigated with Selank. Selank is a synthetic heptapeptide developed in Russia from tuftsin, a naturally occurring peptide fragment associated with the immune system. It has been investigated for potential anxiolytic effects, particularly in people with anxiety-related conditions. Unlike conventional benzodiazepines, Selank is proposed to influence several neurotransmitter pathways rather than acting as a traditional direct GABA receptor agonist. This has attracted interest because anxiety treatment often involves balancing two competing goals: reducing excessive anxiety while preserving alertness, concentration and normal cognitive function. Some of the reported research findings are interesting: - A 2008 clinical study involving 62 patients compared Selank with medazepam, a benzodiazepine. - The researchers reported similar anxiolytic effects between the two treatment groups. - Selank was also associated with reported antiasthenic and psychostimulant effects. - Laboratory research has investigated possible interactions with GABA-related signalling and enkephalin metabolism. However, there is an important limitation. Most of the available research comes from relatively small Russian studies, animal experiments and laboratory investigations. Large, independently replicated clinical trials are lacking. Therefore, Selank should not be described as a proven replacement for established anxiety medications or as a treatment that is definitively safer than benzodiazepines. In this article, we will examine what Selank is, how researchers think it may work, what the clinical studies found and what remains unknown about its safety. What Is Selank? Selank is a synthetic peptide developed by researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences.
0
0
Selank Peptide: Benefits, Mechanism of Action, Anxiety Research and Safety
Do GH Secretagogues Really Need to Be Cycled? What the 52-Week Tesamorelin Study Reveals
An Overview One of the most common questions surrounding growth hormone (GH) secretagogues is whether they need to be cycled. The argument usually centres on receptor desensitisation. Some believe that continuously stimulating the growth hormone pathway could eventually cause receptors to become less responsive, reducing the effectiveness of a compound over time. Tesamorelin is often included in this discussion. But is there clinical evidence that it needs to be stopped periodically to prevent receptor burnout? A useful place to start is a series of randomised, placebo-controlled clinical trials involving adults with HIV-associated lipodystrophy. Researchers followed participants for an initial 26 weeks and then continued monitoring selected participants through a further 26-week extension. The results provide some interesting information about sustained treatment, changes in visceral adipose tissue (VAT), and insulin-like growth factor 1 (IGF-1). The most important findings were: - Tesamorelin reduced visceral adipose tissue compared with placebo during the initial 26-week treatment period. - Participants who continued treatment generally maintained the reduction in visceral fat. - Participants who switched from tesamorelin to placebo experienced a substantial return of visceral fat. - IGF-1 levels declined somewhat during the extension among those continuing treatment, but remained elevated compared with baseline. - Participants who switched to placebo experienced a much larger decline in IGF-1. Does this prove that tesamorelin does not cause receptor desensitisation? No. However, the findings do challenge the idea that its clinical effects necessarily disappear after several months of continuous treatment. In this article, we will examine the clinical evidence, explain the difference between receptor desensitisation and loss of treatment effect, and discuss whether the available research supports cycling GH secretagogues. First, What Are GH Secretagogues?
1
0
Do GH Secretagogues Really Need to Be Cycled? What the 52-Week Tesamorelin Study Reveals
SS-31 Peptide: Benefits, Mechanism of Action, Dosage and Scientific Research
Mitochondria are central to cellular energy production, metabolic activity and several processes involved in maintaining cellular function. Because of their importance, mitochondrial research has become an increasingly active area of scientific investigation. One compound attracting attention in this field is SS-31 peptide, also known as Elamipretide. Unlike compounds that primarily target conventional metabolic pathways, SS-31 has been investigated for its interactions with cardiolipin, a phospholipid found in the inner mitochondrial membrane. Researchers are particularly interested in how these interactions may influence mitochondrial membrane organisation, electron transport, cellular energy production and oxidative stress. Interest in SS-31 peptide benefits has grown alongside research into mitochondrial dysfunction and its potential relationship with different biological conditions. Preclinical experiments and human clinical trials have investigated Elamipretide in several research settings, although the findings vary depending on the condition, study design and measured outcomes. This article examines what SS-31 peptide is, its proposed mechanism of action, what scientific studies have reported, and what published research tells us about SS-31 peptide dosage and dosing protocols. The discussion focuses on scientific research and published evidence. Experimental research protocols should not be interpreted as personal dosing recommendations. What Is SS-31 (Elamipretide)? SS-31 is a synthetic mitochondrial-targeting tetrapeptide that has been investigated for its potential influence on mitochondrial structure and function. It is also known by several other names: - Elamipretide - MTP-131 - Bendavia - SS-31 The compound consists of four amino acids and has a distinctive alternating aromatic-cationic structure. Its molecular sequence is: D-Arg-2′6′-dimethylTyr-Lys-Phe-NH₂ This particular structure is important because it allows SS-31 to interact with mitochondrial membranes, particularly the inner mitochondrial membrane.
2
0
SS-31 Peptide: Benefits, Mechanism of Action, Dosage and Scientific Research
One Year on the Shelf. Two Years Lost in Transit. What Did the Tests Show?
Two separate peptide testing cases raise an interesting question about storage, stability and what laboratory purity results can actually tell us. Peptide stability is a subject that attracts plenty of attention, particularly when products are stored for extended periods or experience unexpected delays during shipping. I recently came across a post from Derek Pruski discussing two interesting peptide testing cases. One involved a batch tested more than a year apart after being stored at room temperature. The other involved a separate batch that had reportedly been lost in transit for approximately two years before being recovered and retested. The results caught my attention because they raised a question worth investigating: how much can a peptide's measured analytical purity change over extended periods, and what can laboratory testing actually tell us about its stability? Rather than simply repeating the claims made in the original post, I wanted to look at the underlying analytical reports and explore the science behind the results. The investigation led me to four Janoshik reports covering two separate batches. The first involves batch PC-J-T40, which was tested twice, with reports dated November 2024 and December 2025. The two reports were issued 395 days apart, and the case is described as a room-temperature storage comparison. The second involves a different batch, PC-Z-T10, which was recovered after approximately two years lost in transit and subsequently retested. Its original reported purity was rounded to 100.00%. There is an important transparency point before going further. Although I could identify the original Janoshik reports, I could not independently access the complete analytical result images needed to verify every reported purity figure. I therefore won't reproduce unverified numbers or calculate a percentage change that cannot be confirmed. This means the article focuses on the reported testing timelines, the science behind peptide stability and the limitations of interpreting individual analytical results.
1
0
One Year on the Shelf. Two Years Lost in Transit. What Did the Tests Show?
Tirzepatide Cut Weight by 50 Pounds. Resistance Training Changed What Happened to Strength.
A new 40-week randomized trial found that resistance training did not stop weight loss from tirzepatide. It changed what happened to lean tissue and muscle strength. GLP-1 and related incretin drugs have changed obesity treatment. Tirzepatide can produce substantial reductions in body weight and fat mass. But there has been an important question hanging over these medications: What happens to lean tissue and muscle function during rapid weight loss? A new randomized controlled trial published in Nature Medicine provides one of the clearest answers yet. The study included 120 adults with overweight or obesity. Everyone received tirzepatide for 40 weeks. Then the participants were divided into two groups. One group continued their usual activities. The other completed supervised resistance training three times per week. Both groups lost roughly the same amount of body weight. Both groups lost substantial amounts of fat. But when researchers measured lean tissue and strength, the results were dramatically different. The headline is simple: Weight loss was similar. Strength was not. The First Randomized Trial of Its Kind According to the researchers, this was the first randomized controlled trial designed to test whether resistance exercise could help manage losses of lean tissue and muscle function during treatment with tirzepatide. The study is known as the: T-REx Trial Participants were: - Between approximately 50 and 70 years old - Overweight or obese - Initially sedentary - Men and postmenopausal women - Treated with tirzepatide for 40 weeks A total of 120 participants entered the trial. They were randomized into: Tirzepatide only Participants continued their usual activities while receiving tirzepatide. Tirzepatide plus resistance exercise Participants received tirzepatide and completed three supervised resistance training sessions each week. The exercise program was progressive and lasted for the entire 40-week intervention. Importantly, adherence was extremely high.
1
0
Tirzepatide Cut Weight by 50 Pounds. Resistance Training Changed What Happened to Strength.
1-10 of 95
Lily Yandex
2
9 points to level up
@lily-yandex-5287
Premium research peptides for scientists, labs, and serious researchers.

Active 13h ago
Joined Aug 20, 2026